
==== Front
Int J Biol Sci
Int J Biol Sci
ijbs
International Journal of Biological Sciences
1449-2288
Ivyspring International Publisher Sydney

10.7150/ijbs.95894
ijbsv20p4178
Review
mTOR Signaling: Roles in Hepatitis B Virus Infection and Hepatocellular Carcinoma
Mei Ling MPH 123
Sun Huizhen PhD 12
Yan Ying PhD 12
Ji Huimin PhD 12
Su Qian PhD 123
Chang Le PhD 123✉
Wang Lunan PhD 123✉
1 National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/ National Center of Gerontology, Beijing, 100730, P.R. China.
2 Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, 100730, P.R. China.
3 National Center for Clinical Laboratories, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, P.R. China.
✉ Corresponding authors: Le Chang; Email: changle4652@bjhmoh.cn; Tel.: +86 10 85133609; Add.: No.1 Dahua Road, Dongcheng District, Beijing 100730, P.R. China. Lunan Wang; Email: lunan99@163.com; Tel.: +86 10 85133609; Add.: No.1 Dahua Road, Dongcheng District, Beijing 100730, P.R. China.
Competing Interests: The authors have declared that no competing interest exists.

2024
1 8 2024
20 11 41784189
3 3 2024
24 7 2024
© The author(s)
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Currently, chronic hepatitis B virus infection is still one of the most serious public health problems in the world. Though current strategies are effective in controlling infection and slowing down the disease process, it remains a big challenge to achieve a functional cure for chronic hepatitis B in a majority of patients due to the inability to clear the cccDNA pool. The mammalian target of rapamycin (mTOR) integrates nutrition, energy, growth factors, and other extracellular signals, participating in gene transcription, protein translation, ribosome synthesis, and other biological processes. Additionally, mTOR plays an extremely important role in cell growth, apoptosis, autophagy, and metabolism. More and more evidence show that HBV infection can activate the mTOR pathway, suggesting that HBV uses or hijacks the mTOR pathway to facilitate its own replication. Therefore, mTOR signaling pathway may be a key target for controlling HBV infection. However, the role of the central cytokine mTOR in the pathogenesis of HBV infection has not yet been systematically addressed. Notably, mTOR is commonly activated in hepatocellular carcinoma, which can progress from chronic hepatitis B. This review systematically summarizes the role of mTOR in the life cycle of HBV and its impact on the clinical progression of HBV infection.

mammalian target of rapamycin
hepatitis B virus
hepatocellular carcinoma
mTOR inhibitors
==== Body
pmcIntroduction

Hepatitis B virus (HBV) infection remains a major global public health concern, with an estimated 257 million individuals worldwide suffering from chronic HBV infection1. Chronic HBV infection can lead to serious progressive liver diseases, such as cirrhosis, liver failure, and hepatocellular carcinoma (HCC)2,3, which is the third leading cause of cancer-related deaths globally4. While effective vaccines have been instrumental in reducing HBV infection rates, particularly in infants, the efficacy of existing medications, including alpha interferon and nucleoside analogues that block viral DNA polymerase is hindered by low rates of sustained response, adverse effects, and the emergence of drug resistance1,5-7. The pathogenesis of HBV infection emphasizes that the specific immune response is not only responsible for viral clearance but also results in hepatocyte inflammatory and regenerative responses. It triggers mitogenic stimuli and mutagenic factors for the formation of DNA damage that can lead to the development of HCC8-12.

It is worth noting that there is a contradiction between the theory of the pathogenesis of HBV infection and the clinical practice of medication. Currently, the pathogenesis emphasizes that the damage caused by HBV infection is mediated by immunity, while the clinical treatment focuses on inhibiting HBV replication to alleviate liver disease. This incongruity raises questions about the need for additional supplements to the pathogenesis of HBV infection, which could enhance our understanding of the disease and optimize the treatment plans. The mammalian target of rapamycin (mTOR) signaling pathway has been found to regulate the life cycle of many viruses13,14, and understanding the role of mTOR in the life cycle of HBV is not only significant for clarifying the pathogenesis of HBV, but also for developing effective treatment strategies15.

HCC is one of the most common tumors worldwide, and its treatment methods include surgical resection, percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), and liver transplantation. However, these methods are only suitable for a small number of patients and often lead to postoperative complications16. Fewer than 10% of HCC patients are cured, and most eventually progress to advanced HCC. At present, only systemic treatment can effectively delay the natural course of the disease17. The current frontline treatment for systemic therapy in clinical practice is the tyrosine kinase inhibitor (TKI) Sorafenib, both the RAF/MEK/ERK pathway and receptor tyrosine kinases to inhibit tumor growth and angiogenesis18. However, its median survival is only 10.7 months19. Given that mTOR is activated in 40% -50% HCC cases20-23, it is essential to elaborate on the role of mTOR in the progression of HCC. This review aims to summarize the latest developments in the interaction between HBV and mTOR, as well as the impact of mTOR on HCC progression.

The structure and function of mTOR

The mTOR protein is a member of the phosphoinositide 3-kinase (PI3K)-related kinase (PIKK) family and is an evolutionarily conserved Ser/Thr kinase. it was discovered that mTOR and yeast TOR/DRR proteins, previously identified as rapamycin targets in genetic tests for rapamycin resistance, shared a similarity24-26. The mTOR protein consists of about 2,500 amino acids and contains functional domains including HEAT repeats, FAT, FRB, Kinase, and FATC (Figure 1). The FAT and FATC domains participate in the interaction between mTOR and its ligands, while the FRB (FKBP12-Rapamycin Binding) domain is involved in the binding of Rapamycin and FKBP12 to inhibit mTOR activity27,28, and the Kinase domain is responsible for the phosphorylation of downstream targets of mTOR. Overall, the structure of mTOR is intricate, with different domains participating in different functions in signal transduction, protein synthesis, and cellular metabolism29.

mTOR is the catalytic subunit of two complexes, mTORC1 and mTORC230 (Figure 1), and their activation and function depend on their subcellular localization 31. These complexes can be distinguished by their specific substrates and activities, auxiliary proteins, and varying sensitivity to rapamycin. Three primary constituents comprise mTORC1: the catalytic subunit mTOR, the regulatory subunit Raptor, and mLST832,33. Raptor guarantees appropriate subcellular localization and aids in the recruitment of substrates into the complex. By attaching itself to the catalytic domain, mLST8 keeps the kinase activation loop stable. In addition to these elements, mTORC1 contains two inhibitory subunits: DEPTOR and PRAS40 (Akt substrate). mTORC2 consists of mLST8, mTOR subunit and Rictor, which is insensitive to rapamycin and comparable with Raptor. Together with the other regulatory subunits, mSin1 and Protor1/2, mTORC2 also contains the inhibitory Deptor subunit34-37.

mTORC1 plays a crucial role in regulating numerous essential cellular processes, including glucose homeostasis, lipid synthesis, and autophagy, by functioning as a sensor for growth factors, pressure, energy status, oxygen, and amino acids38,39. On the other hand, the mTORC2 complex regulates cell survival and cytoskeletal structure34,35. It also participates in the transcription factor forkhead box protein O3 (FOXO3) pathway, which controls autophagy40. Through a negative feedback loop between the mTORC1 and PI3K-AKT pathways, mTORC1 also controls mTORC2 signaling41. Tuberous sclerosis 1 (TSC1) and 2 (TSC2) are key upstream regulators of mTORC1. The GTP-bound form of Ras homolog enriched in the brain (Rheb) directly interacts with mTORC1 and strongly stimulates its kinase activity42-44. However, TSC1/2 negatively regulates mTORC1 activity by reversing Rheb into its inactive GDP-bound state 45,46. Conversely, mTORC2 is a rapamycin-insensitive companion of mTOR47 and can be directly activated by PI3K48,49. Compared with the mTORC1 pathway, the mTORC2 pathway is much less understood. Its downstream targets include several members of the AGC kinase subfamily, such as Akt, serum and glucocorticoid-induced protein kinase 1 (SGK1) and protein kinase C-a (PKC-a). mTORC2 directly activates Akt by phosphorylating the hydrophobic motif (Ser473) of Akt, which is required for its maximum activation50. Akt then regulates cellular metabolism, survival, apoptosis, growth and proliferation through the phosphorylation of several effectors. This involves the classic PI3K-AKT-mTOR pathway.

The growth factor-mediated receptor tyrosine kinases (RTKs)/PI3K/Akt signaling pathway is an important upstream signaling pathway for the mTOR protein molecule51(Figure 2). Upon stimulation by growth factors, the RTKs initiate signaling cascades that activate PI3K. Generally, PI3K activity is tightly controlled to a basal level under normal conditions. Subsequently, PI3K catalyzes the synthesis of phosphatidylinositol 3,4,5-triphosphate (PIP3) by phosphorylating phosphatidylinositol 4,5-bisphosphate (PIP2). This process is antagonized by phosphatase and tensin homolog deleted on chromosome 10 (PTEN), a tumor suppressor that converts PIP3 to PIP252. PIP2 and PIP3 directly interact with the pleckstrin homology (pH) domain of AKT53-55, resulting in its phosphorylation by PDK1 at Thr30856-58. Additionally, the phosphorylation of AKT on Ser473 by mTORC2 is also necessary for its activity50,59. TSC2 undergoes inactivation through Akt-dependent phosphorylation, which destabilizes TSC2 and disrupts its interaction with TSC160, and acts as a GTPase-activating protein (GAP) complex toward the GTPase RAS homolog enriched in the brain (Rheb)61. The mTORC1, a direct target of Rheb-GTP, activates the TOR kinase62. The mobilized mTORC1 then relays signaling by phosphorylating two key substrate protein molecules, p70S6K, and 4E-binding protein1 (4EBP1), resulting in activation of p70S6K at Thr229 and inactivation of 4EBP163. Activated p70S6K subsequently phosphorylates eIF4B to initiate protein synthesis64. 4E-BP1 also releases inhibition on eIF4E to enhance protein synthesis 65,66. Furthermore, mTORC1, similar to yeast TOR, phosphorylates mammalian ULK1, ATG13, and FIP200 complex67,68, thereby inhibiting ULK1 and ULK2 kinase activity by phosphorylating ULK1 at Ser758. Then, the activated ULK1 phosphorylates Beclin-1 at Ser14, which is necessary to induce autophagy49,67,69-72.

HBV infection and mTOR

After the HBV particles enter liver cells through receptor sodium taurocholate cotransporting polypeptide (NTCP) and heparan sulfate proteoglycan (HSPG)73,74, they undergo uncoating in the nucleus, and relaxed circular DNA (rcDNA) is released from the nucleocapsid into the liver nucleus. The rcDNA is converted into the template cccDNA75,76, which is transcribed and then translated to L-HBsAg, M-HBsAg, S-HBsAg, HBx proteins, HBeAg, and core proteins77. In some cases, these viral proteins can affect the normal physiological activities of liver cells, resulting in ER stress, activating mTOR, and ultimately leading to the progression of liver-related diseases such as cirrhosis and liver cancer (Figure 3).

HBx protein activate mTOR

The HBV genome consists of four overlapping open reading frames (ORFs). One of these, ORFs X, encodes the small non-structural regulatory HBV X protein (HBx). HBx is composed of 154 amino acids and has a molecular mass of about 17.5 kDa78. The multifunctional HBx protein interacts with several host factors to affect cellular signal transduction pathways, transcriptional regulation, cell cycle progression, DNA repair, apoptosis, and genetic stability79.

Early research found that in vitro cell experiments conducted on Chinese Hamster Lung cells showed that, compared to the control group, cells transfected with HBx exhibited significantly higher PI3K and Akt activities80. However, this study did not use the liver cell line. Subsequently, experiments on human liver cancer cell lines and HBx-transgenic mice have demonstrated that overexpression of HBx increases the level of phospho-S6K1, which is downstream of mTOR81.

Further studies suggested that the expression of p-mTOR and its upstream p-AKT was significantly upregulated in liver-derived cells after transfection with HBx82-84. This upregulation leads to increased cell proliferation, which is also linked to inflammation and tumor angiogenesis. The occurrence of this result is based on the following clarified mechanisms: (1) HBx inhibits TSC1 and then activates mTOR through the IκB kinase (IKK) complex subunit β (IKK-β), ultimately promoting cell proliferation and new vessel formation by enhancing vascular endothelial growth factor A (VEGF-A), which promotes malignant transformation of liver cells81,85. (2) HBx prevented hepatocyte apoptosis and accelerated the cell cycle from the G1 phase to the S phase by increasing the expression of cyclinD1 through the Akt/mTOR signaling pathway82,83,86-88. (3) HBX induced Alpha-fetoprotein (AFP) expression to activate the PI3K/AKT/mTOR signaling pathway by binding PTEN with AFP, and then p-mTOR (Ser2448) enhanced HIF-1α binding to the promoters of Src, C-X-C chemokine receptor 4 (CXCR4), and Ras genes, which are oncogenes89. Or p-mTOR (Ser2448) promotes CXCR4 expression through binding to CXCR4 gene promoter elements directly90. Finally, overexpression of these oncogenes promotes invasion and metastasis in hepatocytes91-95. To summarize, it can be observed that mTOR signaling plays an important role as a molecular regulatory factor in connecting metabolic disorders and cancer in chronic HBV infection (Figure 3).

HBsAg activates mTOR

According to the research, accumulating wild-type and mutant HBsAg can cause ER stress and turn on the Akt/mTOR signaling pathway to induce cell transformation and inflammation96-99. Particularly, the overexpression of large hepatitis B surface antigen (L-HBsAg) may participate in HBV-related hepatocarcinogenesis by activating the PI3K/Akt/mTOR pathway100. Besides, overexpression of small hepatitis B surface antigen (S-HBsAg) cannot change the phosphorylation levels of mTOR101. Additionally, numerous studies have shown that mutations in the pre-S region are associated with the formation of liver cancer through the mediating mTOR signaling pathway, which is situated within the coding region of L-HBsAg 97,102-110.

Firstly, pre-S1/2 deletion mutants (pre-S1: nt 3040-3111, pre-S2 mutant: nt 4-57) induced the enhanced expression of p-Akt and p-mTOR in HuH-7 cells97. The pre-S2 deletion mutant-induced mTOR activation signal cascade can not only promote lipogenesis by activating key regulators of lipid metabolism, such as sterol regulatory element binding transcription factor 1 (SREBF1) and ATP citrate lyase (ACLY), but also stimulate cell proliferation, both of which may lead to the occurrence of HCC108. Besides, pre-S2 deletion mutants may activate mTOR/Yin Yang 1(YY1) /myelocytomatosis oncogene (MYC) signaling to upregulate SLC2A1, which would sustain high activation rates of aerobic glycolysis and lead to tumorigenesis109,110. Interestingly, Teng et al. indicated that some pre-S1 deletions and site mutants can activate mTOR in HuH-7 cells. In turn, the up-regulated mTOR inhibited L-HBsAg synthesis at the transcriptional stage through the transcription factor YY1, which binds to the preS1 promoter (nt 2812-2816)102.

mTOR affects the transcription and replication of HBV

mTOR inhibits HBV transcription and replication. Related studies have shown that constitutively active Akt1 significantly suppressed HBV RNA transcription, which in turn decreased HBV DNA replication. Given that the mTOR inhibitor rapamycin reversed this decrease in HBV gene transcription, it appears that mTOR activation was the cause111. Besides, treatment with mTOR inhibitors (rapamycin) on HepG2.2.15 cells increased the transcription of 3.5-kb and 2.4-kb viral RNA, the replication of HBV DNA within the cell, and the secretion of HBeAg and HBsAg 111-113. In addition, when using small interfering RNA (siRNA) specific to Akt and mTOR, similar to the use of chemical inhibitors, HBV replication and secretion of HBsAg and HBeAg were also significantly increased112,113. Another study found that these inhibitors enhance HBV replication and transcription in an HBx-dependent manner114. Furthermore, in HBV-infected dHepaRG cells, prolonged treatment with PI3K-AKT inhibitors also increased the extracellular HBV DNA114.

The specific physiological mechanism impacting the replication of HBV following the activation of the Akt/mTOR signaling pathway is based on autophagy112,113,115. Studies have shown that inhibiting the mTOR/ULK1 signaling pathway promotes autophagy, thereby upregulating HBV replication113,116. Conversely, knocking down the downstream effector ULK1 results in a significant decrease in HBV replication as well as HBsAg and HBeAg secretion in HepG2.2.15 cells. ULK1, as a classic autophagy mediator, is essential for the initiation of autophagosome formation117,118. and silencing ULK1 significantly reduces the frequency of autophagic puncta113. The formation of autophagic cells is crucial for the effective replication of HBV in various cells and animal models during HBV infection101,115,116,119-123. If autophagy is suppressed, there is only a slight reduction in HBV RNA levels and pgRNA packaging. However, it significantly inhibits HBV DNA replication. This indicates autophagy primarily enhances HBV replication during the process of viral DNA replication115. In turn, HBV can induce the formation of autophagic lysosomes in liver cells, as supported by in vitro cell experiments, animal experiments using HBV transgenic mice, and clinical pathology. It is worth noting that HBV enhances autophagy flux without increasing the degradation rate of autophagic proteins, suggesting a positive role of autophagy in HBV DNA replication115.

Non-viral HCC and mTOR

The mTOR signaling pathway is frequently dysregulated in cancer and metabolic diseases124. Constitutive activation of the mTOR pathway may cause diet-independent HCC125. A comprehensive microarray study on a large number of human hepatocellular carcinoma patients shows that activation of Akt1 is one of the most consistent characteristics of HBV-induced HCC126. Inhibition of the PI3K/Akt/mTOR pathway can induce apoptosis and autophagy in hepatocellular carcinoma cells127. The previous mentioned evidence has shown that HBV infection can regulate the activity of the mTOR signaling pathway through different mechanisms, thus affecting the occurrence and development of HCC. However, some non-HBV infection factors can also lead to the activation of mTOR, which in turn leads to the occurrence of HCC (Figure 3).

Due to the liver being an organ for fat metabolism, the impact of mTOR on the development of HCC through lipid metabolism cannot be ignored in the special microenvironment of hepatocytes. The process of aliphatic acid production by hepatocytes is mediated by insulin through the PI3K/AKT/mTOR signaling pathway. Imbalance in mTOR pathway can lead to the production of lipid synthesis intermediates, which can ultimately result in steatosis and cancer128,129. The enhancement of lipid synthesis leads to the pathological accumulation of fatty acids(FA), thereby promoting inflammation and contributing to tumor progression130. It is found that mTORC2 can regulate the expression of certain key lipid synthesis genes at the transcriptional level128. However, on the contrary, another study suggested that the imbalance in the mTOR pathway is associated with cancer, rather than the development of liver steatosis125. In addition to lipid synthesis, mTOR can also regulate lipid lipolysis and the mobilization of lipid storage in liver cells by regulating autophagy and lysosomes131-133.

mTOR inhibitor treatment in HCC

Due to the abnormal activation of the mTOR pathway in 40% to 50% of HCC patients134-136, there is growing interest in developing HCC treatment strategies that target mTOR. First generation mTOR inhibitors are Rapamycin (also known as Sirolimus) and its derivatives, targeting mTOR and FKBP12 to directly inhibit mTORC1. Derivatives include medications such as Temsirolimus (CCI-779), Deforolimus (AP23573), and Everolimus (RAD001)137. Some of them have been approved by the FDA for the treatment of advanced renal cell carcinoma or neuroendocrine tumors. For example, Sirolimus has been approved by the FDA for reducing organ rejection in patients undergoing renal transplantation in 1999138-140, and temsirolimus has been approved by the FDA for patients with advanced renal cell carcinoma (RCC) in 2007141. Besides, Everolimus was approved by the FDA for the treatment of adult patients with specific pulmonary and gastrointestinal neuroendocrine tumors in 2016142,143. Although the second and third generations of mTOR inhibitors have been developed, the majority of current clinical trials related to HCC still choose the first generation for research. Recent years, mTOR inhibitors have shown effectiveness in inhibiting the growth of HCC cells in both cell and animal experiments144-146. However, clinical trials conducted to test the efficacy of Rapalogs in treating HCC showed mixed results (Table 1).

For patients with advanced-stage HCC, the first-line treatment drug is the multi-kinase inhibitor Sorafenib147. However, when combined with Everolimus, there is no improved efficacy compared to Sorafenib alone148. Additionally, using single-agent Sirolimus was found to be modestly beneficial for patients. While Everolimus combined with the best supportive care did not improve survival compared to the placebo group149,150. Except for Everolimus and Sirolimus, Termosimox also fails to achieve the targeted progression free survival (PFS) endpoint of HCC151. However, intravenous injection of Termosimox showed a higher response in HCC compared to previously reported systemic Prescription152. Despite compelling preclinical evidence and scientific justification20,22,23,144,146,153,154, mTOR inhibitors demonstrated only modest efficacy in advanced HCC patients.

Owing to the limited effectiveness of Rapalogs as a standalone therapy for HCC, numerous clinical trials have been conducted or are currently underway to evaluate their therapeutic efficacy in combination therapies. Temsirolimus in combination with Bevacizumab increased the objective response rate (ORR) and overall survival (OS) in this population with advanced HCC155, which is promising but calls for more research at a more optimal dose and timing. The therapeutic efficacy of Sirolimus/ Bevacizumab doublet for advanced HCC also showed evidence of anti-vascular activity156. The differences in the effectiveness of mTOR inhibitors in single and combination therapies may be due to the complexity of the mTOR pathway and the heterogeneity of liver tumors.

mTOR inhibitors are not only effective in treating advanced HCC but also demonstrate impressive efficacy following liver transplantation for HCC. In the clinical trials of Sirolimus as adjuvant therapy after liver transplantation for HCC, it significantly prolonged OS and reduced the risk of death. Significantly, the benefits of Sirolimus in the initial 3-5 years of recurrence free survival (RFS) and OS are more pronounced in low-risk patients compared to high-risk groups157. Moreover, subgroups with AFP≥10ng/ml benefited mostly from sirolimus treatment, which improved OS, disease free survival (DFS) and HCC recurrence158,159. Therefore, focusing on the subgroups of HCC patients in clinical trials of mTOR inhibitors may be more promising.

The above clinical experiments have shown that the success of raptalogs in the treatment of HCC is not significant, and the limited therapeutic effect may be due to the following reasons: (1) mTORC1 inhibition leads to AKT activation through a negative feedback loop stemming from S6K1 or upregulating the insulin-like growth factor-1 receptor (IGF-R1)160,161. Therefore, it may actually reduce the anticancer activity of rapalogs162. (2) Raptalogs mainly inhibits its substrate S6K, which is related to cell proliferation. But another key substrate, 4E-BP1, has not been fully blocked163. (3) Patients exhibit rapamycin resistance mutations in the FRB domain of mTOR after or before treatment 164,165. Furthermore, elevated amounts of the antiapoptotic proteins Bcl-2, survivin, or Bcl-XL have resulted in rapalog resistance166-169. Therefore, genetic testing can be performed before medication to prevent rapalog resistance from delaying treatment.

In addition, mTORC1 can also be inhibited by acyclic nucleoside phosphonates (ANPs) in vitro, which are a kind of nucleoside analogue for clinical use of HBV infection. Studies have shown that ANPs reduce IL-10 production by inhibiting mTOR, and downregulation of IL-10 may promote HBV clearance in vivo by restoring the function of T cells and NK cells 170-172. Can nucleoside analogues contribute to inhibit HCC development? However, in another article, activation of mTOR was found in the liver tissue of patients taking the same type of ANP (ADV or TDF)173. Considering the presence of two complexes of mTOR, further research is needed on the specific effects of nucleoside analogues on mTOR and HCC progression.

Summary and Outlook

This review has illustrated the pivotal role of mTOR in the nexus of nutrition, growth, aging, and disease, particularly in the replication of HBV particles at the level of DNA replication, RNA transcription, and antigen secretion. Simultaneously, activated mTOR, serving as an important carcinogenic pathway, also exhibits intricate interactions in HBV-related and non-viral HCC. Some studies suggest that the pathogenesis of HBV is attributed to the high-level replication of the virus, as the continuous accumulation of transcription templates will lead to the damage of infected cells. This elevated level of replication will lead to the consumption of cellular resources, such as synthetic cell membranes, lipoproteins, phospholipids, etc182. Additionally, mTOR is the central regulatory factor for nutrition and growth. Therefore, in the pathogenesis of HBV, mTOR is likely to have special regulation. The activation of mTOR signaling pathway during HBV-related tumorigenesis negatively regulates HBV replication and surface antigen synthesis. Therefore, the decrease of HBsAg and HBV DNA levels in serum or liver cells may not necessarily represent favorable disease improvement during the natural course of HCC, but on the contrary, it may suggest that the disease is developing toward a tumor, especially in the late stage of the disease. Considering the important role of the mTOR signaling pathway in various types of cancer183-185, currently, many rapamycin analogs, such as Everolimus and Temsirolimus, have been approved by the Food and Drug Administration186, Previous studies reported the importance of completely inhibiting mTORC1 effectors (RPS6 and eIF4E) in hepatocarcinogenesis187. In addition to treating HCC, mTOR inhibitors have also been found to be effective in reducing HCC recurrence after liver transplantation188. Moreover, the study of mTOR and its impact on the life cycle of HBV is valuable for the development of safe and effective therapies against viral effects. Although there have been many studies on mTOR signaling pathway in carcinogenesis, the unique characteristics of liver cells and the particularity of the HBV life cycle make the exploration of mTOR in HBV-related HCC both meaningful and worthy of further investigation.

Funding

This work was supported by the grants from the National Natural Science Foundation of China (No. 82202612) and the Natural Science Foundation of Beijing Municipal (No.7232142).

Figure 1 The composition of both mTORC1 and mTORC1. mTORC1 comprises a core of mTOR, mLST8, and Raptor that is suppressed by PRAS40 and DEPTOR. mTORC2 is composed of a basic complex of mTOR, mLST8, and Rictor, which is inhibited by DEPTOR and regulated by mSin1 and Protor1/2. A combination consisting of rapamycin and the cytoplasmic receptor FKBP12 binds to the FRB domain, allosterically inhibiting mTOR action.

Figure 2 The mTORC1/2 signaling pathways. The receptor tyrosine kinases (RTKs)/PI3K/Akt signaling pathway, stimulated by growth factors, is pivotal to mTOR protein regulation. PI3K, typically maintained at a basal level, is activated to synthesize phosphatidylinositol 3,4,5-triphosphate (PIP3) from phosphatidylinositol 4,5-bisphosphate (PIP2). This process is counteracted by the tumor suppressor PTEN. PIP2 and PIP3 trigger AKT phosphorylation, leading to TSC2 inactivation and Rheb-GTP generation. Upon phosphorylation by mTORC1, ULK1/2 induces autophagy by phosphorylating Beclin-1.

Figure 3 The Interaction between mTOR pathway and HCC. HBx activates the PI3K/AKT/mTOR signaling pathway by increasing the expression of AFP and activating IKKβ, which encourages malignant transformation. Besides, the accumulation of mutant L-HBsAg and excessive L-HBsAg could also activate the mTOR signaling pathway. Then the activated mTOR promotes carcinogenic-related life activities, such as aerobic glycolysis, angiogenesis, lipogenesis, migration, inflammation, and cell cycle.

Table 1 Summary of completed clinical trials with mTOR inhibitors in HCC

	Drug	Trail Phase	Number of enrolled patients	HCC Stage	Child-Pugh Score	Study design	Countries And Regions	Result	ID	
Adjuvant therapy after liver transplantation	Sirolimus vs mTOR inhibitor free	III	510	Milan criteria and extended	NA	Randomized	global multicenter	Completed157,158,174.
Sirolimus prolonged OS and reduced the risk of death.	NCT00355862	
III	397	Exceeding the Milan criteria	NA	Non-randomized	China	Not yet completed175.	ChiCTR2100042869	
Sirolimus vs Tacrolimus	II	45	Exceeding the Milan criteria	NA	Randomized	Korea	Completed 159.
While sirolimus prolongs OS, it does not reduce HCC recurrence.	NCT01374750	
III	220	Exceeding the Milan criteria	NA	Randomized	China	Recruiting.	NCT00554125	
Adjuvant therapy after TACE	TACE +/- Everolimus	I/II	27	Intermediate stage B	A, B (<8)	Randomized	Switzerland multicenter	The study was terminated due to low enrollment.	NCT01009801	
II	65	Intermediate stage B	A, early B	Randomized	Asia, multicenter	This study was terminated due to low enrollment.	NCT01379521	
Single agent for advanced HCC	Sirolimus	pilot	21	I to IV (TNM)	A/B/C	Non-randomized	Sweden	Completed176.
A temporary disease-control rate (PR + SD) was observed.	NA	
II	25	B,C (BCLC)	A/B	Non-randomized	France	Completed 177.
Sirolimus shows antitumoural efficacy.	Sirolimus	
pilot	18	B,C,D (BCLC)	A/B/C	Non-randomized	Austria	Completed 150.
Sirolimus shows minimal effectiveness in patients with liver cirrhosis and advanced HCC.	NA	
Temsirolimus	II	45	advanced	A	Non-randomized	Hong Kong, China	Completed 151.
The targeted PFS endpoint was not reached.	NCT00321594	
II	25	advanced	A/B	NA	America	Completed 152.
Temsirolimus showed higher responses than previous report.	NCT01567930	
Everolimus	I/II	28	B,C (BCLC)	A/B	Non-randomized	America	Completed178.
Everolimus was observed initial anticancer activity.	NA	
I/II	39	advanced	A, B(≤9)	Randomized	Taiwan, China	Completed179.
This study recommends that future HCC studies on the dosage of everolimus should be conducted at a dose of 7.5mg/day.	NCT00390195	
III	546	advanced	A	Randomized	global multicenter	Completed 149.
The OS of patients with HCC was not improved by everolimus.	NCT01035229	
Adjuvant combination therapy for advanced HCC	Sorafenib and Temsirolimus	I	25	III, IV	A, B (≤7)	Non-randomized	America multicenter	Completed180.
The maximum-tolerated dose (MTD) was sorafenib 200 mg twice daily plus temsirolimus 10mg/week.	NA	
I	25	III, IV (AJCC)	A, B (≤7)	Non-randomized	America multicenter	Not yet published.	NCT01008917	
II	29	II,III,IV(AJCC)	A, B (≤7)	Non-randomized	America multicenter	Not yet published.	NCT01687673	
Sorafenib and Everolimus	II	30	advanced	A	Randomized	America	Completed 181.
The MTD was sorafenib 400 mg twice daily plus everolimus 2.5mg/day.	NA	
II	106	B,C (BCLC)	A, B (≤7)	Randomized	global multicenter	Completed148.
Sorafenib and Everolimus combination failed to improve the efficiency compared to Sorafenib solely.	NCT01005199	
Temsirolimus + Bevacizumab	II	28	advanced	A	NA	Canada	Completed 155.
The overall response rate and median OS have both improved under Temsirolimus and Bevacizumab combination therapy.	NCT01010126	
Everolimus+ Bevacizumab	II	36	B,C (BCLC)	A/B	randomized	Germany multicenter	Not yet published.	NCT00775073	
Sirolimus + Bevacizumab	II	27	advanced	A/B	Non-randomized	Singapore	Completed156.
The recommended dose was bevacizumab
5mg/kg /14 days and rapamycin 4 mg/day.	NCT00467194	
Everolimus and Pasireotide	II	24	C (BCLC)	A(≤6)	randomized	America multicenter	Not yet published.	NCT01488487
==== Refs
1 Liang TJ Block TM McMahon BJ Present and future therapies of hepatitis B: From discovery to cure Hepatology 2015 62 1893 908 26239691
2 Tang LSY Covert E Wilson E Kottilil S Chronic Hepatitis B Infection: A Review JAMA 2018 319 1802 13 29715359
3 McMahon BJ Epidemiology and natural history of hepatitis B Semin Liver Dis 2005 25 Suppl 1 3 8 16103976
4 Forner A Llovet JM Bruix J Hepatocellular carcinoma Lancet 2012 379 1245 55 22353262
5 Subic M Zoulim F How to improve access to therapy in hepatitis B patients Liver Int 2018 38 Suppl 1 115 21 29427482
6 Fanning GC Zoulim F Hou J Bertoletti A Therapeutic strategies for hepatitis B virus infection: towards a cure Nat Rev Drug Discov 2019 18 827 44 31455905
7 Locarnini S Molecular virology and the development of resistant mutants: implications for therapy Semin Liver Dis 2005 25 Suppl 1 9 19 16103977
8 Chisari FV Ferrari C Hepatitis B virus immunopathology Springer Semin Immunopathol 1995 17 261 81 8571172
9 Shimizu Y T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection World J Gastroenterol 2012 18 2443 51 22654441
10 Guidotti LG Rochford R Chung J Shapiro M Purcell R Chisari FV Viral clearance without destruction of infected cells during acute HBV infection Science 1999 284 825 9 10221919
11 Wieland SF Spangenberg HC Thimme R Purcell RH Chisari FV Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees Proc Natl Acad Sci U S A 2004 101 2129 34 14764900
12 Wieland S Thimme R Purcell RH Chisari FV Genomic analysis of the host response to hepatitis B virus infection Proc Natl Acad Sci U S A 2004 101 6669 74 15100412
13 Bossler F Hoppe-Seyler K Hoppe-Seyler F PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells Int J Mol Sci 2019 20 2188 31058807
14 Ranadheera C Coombs KM Kobasa D Comprehending a Killer: The Akt/mTOR Signaling Pathways Are Temporally High-Jacked by the Highly Pathogenic 1918 Influenza Virus EBioMedicine 2018 32 142 63 29866590
15 Wang X Wei Z Jiang Y Meng Z Lu M mTOR Signaling: The Interface Linking Cellular Metabolism and Hepatitis B Virus Replication Virol Sin 2021 36 1303 14 34580816
16 Anwanwan D Singh SK Singh S Saikam V Singh R Challenges in liver cancer and possible treatment approaches Biochim Biophys Acta Rev Cancer 2020 1873 188314 31682895
17 Llovet JM Montal R Sia D Finn RS Molecular therapies and precision medicine for hepatocellular carcinoma Nat Rev Clin Oncol 2018 15 599 616 30061739
18 Abdelgalil AA Alkahtani HM Al-Jenoobi FI Sorafenib Profiles Drug Subst Excip Relat Methodol 2019 44 239 66 31029219
19 Llovet JM Ricci S Mazzaferro V Sorafenib in advanced hepatocellular carcinoma N Engl J Med 2008 359 378 90 18650514
20 Sahin F Kannangai R Adegbola O Wang J Su G Torbenson M mTOR and P70 S6 kinase expression in primary liver neoplasms Clin Cancer Res 2004 10 8421 5 15623621
21 Schumacher G Oidtmann M Rueggeberg A Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth World J Gastroenterol 2005 11 1420 5 15770715
22 Sieghart W Fuereder T Schmid K Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation Transplantation 2007 83 425 32 17318075
23 Semela D Piguet A-C Kolev M Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma J Hepatol 2007 46 840 8 17321636
24 Heitman J Movva NR Hall MN Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast Science 1991 253 905 9 1715094
25 Cafferkey R Young PR McLaughlin MM Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity Mol Cell Biol 1993 13 6012 23 8413204
26 Kunz J Henriquez R Schneider U Deuter-Reinhard M Movva NR Hall MN Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression Cell 1993 73 585 96 8387896
27 Choi J Chen J Schreiber SL Clardy J Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP Science 1996 273 239 42 8662507
28 Jacinto E Hall MN Tor signalling in bugs, brain and brawn Nat Rev Mol Cell Biol 2003 4 117 26 12563289
29 Yang H Rudge DG Koos JD Vaidialingam B Yang HJ Pavletich NP mTOR kinase structure, mechanism and regulation by the rapamycin-binding domain Nature 2013 497 217 23 23636326
30 Wullschleger S Loewith R Hall MN TOR signaling in growth and metabolism Cell 2006 124 471 84 16469695
31 Betz C Hall MN Where is mTOR and what is it doing there? J Cell Biol 2013 203 563 74 24385483
32 Kim D-H Sarbassov DD Ali SM mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 2002 110 163 75 12150925
33 Hara K Maruki Y Long X Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action Cell 2002 110 177 89 12150926
34 Sabatini DM Twenty-five years of mTOR: Uncovering the link from nutrients to growth Proc Natl Acad Sci U S A 2017 114 11818 25 29078414
35 Saxton RA Sabatini DM mTOR Signaling in Growth, Metabolism, and Disease Cell 2017 169 361 71
36 Samidurai A Kukreja RC Das A Emerging Role of mTOR Signaling-Related miRNAs in Cardiovascular Diseases Oxid Med Cell Longev 2018 2018 6141902 30305865
37 Liu GY Sabatini DM mTOR at the nexus of nutrition, growth, ageing and disease Nat Rev Mol Cell Biol 2020 21 183 203 31937935
38 Hay N Sonenberg N Upstream and downstream of mTOR Genes Dev 2004 18 1926 45 15314020
39 Kim YC Guan K-L mTOR: a pharmacologic target for autophagy regulation J Clin Invest 2015 125 25 32 25654547
40 Plas DR Thompson CB Akt activation promotes degradation of tuberin and FOXO3a via the proteasome J Biol Chem 2003 278 12361 6 12517744
41 Hsu PP Kang SA Rameseder J The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling Science 2011 332 1317 22 21659604
42 Jewell JL Russell RC Guan K-L Amino acid signalling upstream of mTOR Nat Rev Mol Cell Biol 2013 14 133 9 23361334
43 Laplante M Sabatini DM mTOR signaling in growth control and disease Cell 2012 149 274 93 22500797
44 Dibble CC Manning BD Signal integration by mTORC1 coordinates nutrient input with biosynthetic output Nat Cell Biol 2013 15 555 64 23728461
45 Inoki K Li Y Xu T Guan K-L Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling Genes Dev 2003 17 1829 34 12869586
46 Tee AR Manning BD Roux PP Cantley LC Blenis J Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb Curr Biol 2022 32 733 4 35134350
47 Jacinto E Loewith R Schmidt A Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive Nat Cell Biol 2004 6 1122 8 15467718
48 Sarbassov DD Ali SM Kim D-H Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol 2004 14 1296 302 15268862
49 Shimobayashi M Hall MN Making new contacts: the mTOR network in metabolism and signalling crosstalk Nat Rev Mol Cell Biol 2014 15 155 62 24556838
50 Sarbassov DD Guertin DA Ali SM Sabatini DM Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 2005 307 1098 101 15718470
51 Oldham S Hafen E Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control Trends Cell Biol 2003 13 79 85 12559758
52 Lawlor MA Alessi DR PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001 114 2903 10 11686294
53 Franke TF Kaplan DR Cantley LC Toker A Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate Science 1997 275 665 8 9005852
54 Frech M Andjelkovic M Ingley E Reddy KK Falck JR Hemmings BA High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity J Biol Chem 1997 272 8474 81 9079675
55 Klippel A Kavanaugh WM Pot D Williams LT A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain Mol Cell Biol 1997 17 338 44 8972214
56 Stephens L Anderson K Stokoe D Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B Science 1998 279 710 4 9445477
57 Alessi DR James SR Downes CP Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha Curr Biol 1997 7 261 9 9094314
58 Stokoe D Stephens LR Copeland T Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B Science 1997 277 567 70 9228007
59 Alessi DR Andjelkovic M Caudwell B Mechanism of activation of protein kinase B by insulin and IGF-1 EMBO J 1996 15 6541 51 8978681
60 Inoki K Li Y Zhu T Wu J Guan K-L TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat Cell Biol 2002 4 648 57 12172553
61 Tee AR Manning BD Roux PP Cantley LC Blenis J Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb Curr Biol 2003 13 1259 68 12906785
62 Long X Lin Y Ortiz-Vega S Yonezawa K Avruch J Rheb binds and regulates the mTOR kinase Curr Biol 2005 15 702 13 15854902
63 Burnett PE Barrow RK Cohen NA Snyder SH Sabatini DM RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1 Proc Natl Acad Sci U S A 1998 95 1432 7 9465032
64 Holz MK Ballif BA Gygi SP Blenis J mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events Cell 2005 123 569 80 16286006
65 Hara K Yonezawa K Kozlowski MT Regulation of eIF-4E BP1 phosphorylation by mTOR J Biol Chem 1997 272 26457 63 9334222
66 Gingras AC Gygi SP Raught B Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism Genes Dev 1999 13 1422 37 10364159
67 Jung CH Jun CB Ro S-H ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery Mol Biol Cell 2009 20 1992 2003 19225151
68 Ganley IG Lam DH Wang J Ding X Chen S Jiang X ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy J Biol Chem 2009 284 12297 305 19258318
69 Neufeld TP TOR-dependent control of autophagy: biting the hand that feeds Curr Opin Cell Biol 2010 22 157 68 20006481
70 Alers S Löffler AS Wesselborg S Stork B Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks Mol Cell Biol 2012 32 2 11 22025673
71 Jung CH Seo M Otto NM Kim D-H ULK1 inhibits the kinase activity of mTORC1 and cell proliferation Autophagy 2011 7 1212 21 21795849
72 Russell RC Tian Y Yuan H ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase Nat Cell Biol 2013 15 741 50 23685627
73 Yan H Zhong G Xu G Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus Elife 2012 1 e00049 23150796
74 Sureau C Salisse J A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant Hepatology 2013 57 985 94 23161433
75 Rabe B Glebe D Kann M Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events J Virol 2006 80 5465 73 16699026
76 Nassal M HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B Gut 2015 64 1972 84 26048673
77 Bruss V Hepatitis B virus morphogenesis World J Gastroenterol 2007 13 65 73 17206755
78 Bouchard MJ Schneider RJ The enigmatic X gene of hepatitis B virus J Virol 2004 78 12725 34 15542625
79 Motavaf M Safari S Saffari Jourshari M Alavian SM Hepatitis B virus-induced hepatocellular carcinoma: the role of the virus x protein Acta Virol 2013 57 389 96 24294951
80 Lee YI Kang-Park S Do SI Lee YI The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade J Biol Chem 2001 276 16969 77 11278872
81 Yen C-J Lin Y-J Yen C-S Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma PLoS One 2012 7 e41931 22848663
82 Wang P Guo Q-S Wang Z-W Qian H-X HBx induces HepG-2 cells autophagy through PI3K/Akt-mTOR pathway Mol Cell Biochem 2013 372 161 8 23001846
83 Wang H-Y Yang S-L Liang H-F Li C-H HBx Protein Promotes Oval Cell Proliferation by Up-Regulation of Cyclin D1 via Activation of the MEK/ERK and PI3K/Akt Pathways Int J Mol Sci 2014 15 3507 18 24577313
84 Liu Y Xu L Lu B LncRNA H19/microRNA-675/PPARα axis regulates liver cell injury and energy metabolism remodelling induced by hepatitis B X protein via Akt/mTOR signalling Mol Immunol 2019 116 18 28 31574452
85 Lee D-F Kuo H-P Chen C-T IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway Cell 2007 130 440 55 17693255
86 Kato JY Sherr CJ Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1 Proc Natl Acad Sci U S A 1993 90 11513 7 7505440
87 Qie S Diehl JA Cyclin D1, cancer progression, and opportunities in cancer treatment J Mol Med (Berl) 2016 94 1313 26 27695879
88 Wang X Huo B Liu J Huang X Zhang S Feng T Hepatitis B virus X reduces hepatocyte apoptosis and promotes cell cycle progression through the Akt/mTOR pathway in vivo Gene 2019 691 87 95 30630095
89 Zhu M Guo J Li W Hepatitis B virus X protein induces expression of alpha-fetoprotein and activates PI3K/mTOR signaling pathway in liver cells Oncotarget 2015 6 12196 208 25682869
90 Zhu M Guo J Xia H Alpha-fetoprotein activates AKT/mTOR signaling to promote CXCR4 expression and migration of hepatoma cells Oncoscience 2015 2 59 70 25815363
91 Darash-Yahana M Pikarsky E Abramovitch R Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis FASEB J 2004 18 1240 2 15180966
92 Vandercappellen J Van Damme J Struyf S The role of CXC chemokines and their receptors in cancer Cancer Lett 2008 267 226 44 18579287
93 Zlotnik A New insights on the role of CXCR4 in cancer metastasis J Pathol 2008 215 211 3 18523970
94 Xiang Z-L Zeng Z-C Tang Z-Y Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival BMC Cancer 2009 9 176 19508713
95 Zeng H Wei W Xu X Chemokine (C-X-C motif) receptor 4 RNA interference inhibits bone metastasis in breast cancer Oncol Lett 2014 8 77 81 24959222
96 Jing Z-T Liu W Wu S-X Hepatitis B Virus Surface Antigen Enhances the Sensitivity of Hepatocytes to Fas-Mediated Apoptosis via Suppression of AKT Phosphorylation J Immunol 2018 201 2303 14 30171166
97 Yang J-C Teng C-F Wu H-C Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis Hepatology 2009 49 1962 71 19475690
98 Choi Y-M Lee S-Y Kim B-J Naturally Occurring Hepatitis B Virus Mutations Leading to Endoplasmic Reticulum Stress and Their Contribution to the Progression of Hepatocellular Carcinoma Int J Mol Sci 2019 20 597 30704071
99 Appenzeller-Herzog C Hall MN Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling Trends Cell Biol 2012 22 274 82 22444729
100 Liu H Xu J Zhou L Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway Cancer Res 2011 71 7547 57 21994334
101 Li J Liu Y Wang Z Subversion of cellular autophagy machinery by hepatitis B virus for viral envelopment J Virol 2011 85 6319 33 21507968
102 Teng C-F Wu H-C Tsai H-W Shiah H-S Huang W Su I-J Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy Hepatology 2011 54 1199 207 21735472
103 Levrero M Zucman-Rossi J Mechanisms of HBV-induced hepatocellular carcinoma J Hepatol 2016 64 S84 101 27084040
104 Yang Y Sun J-W Zhao L-G Bray F Xiang Y-B Quantitative evaluation of hepatitis B virus mutations and hepatocellular carcinoma risk: a meta-analysis of prospective studies Chin J Cancer Res 2015 27 497 508 26543337
105 Chen C-H Changchien C-S Lee C-M Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study J Infect Dis 2008 198 1634 42 18939932
106 Huang H-P Hsu H-Y Chen C-L Pre-S2 deletions of hepatitis B virus and hepatocellular carcinoma in children Pediatr Res 2010 67 90 4 19816238
107 Yeung P Wong DK-H Lai C-L Fung J Seto W-K Yuen M-F Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B J Infect Dis 2011 203 646 54 21227916
108 Teng C-F Wu H-C Hsieh W-C Tsai H-W Su I-J Activation of ATP citrate lyase by mTOR signal induces disturbed lipid metabolism in hepatitis B virus pre-S2 mutant tumorigenesis J Virol 2015 89 605 14 25339766
109 Teng C-F Hsieh W-C Wu H-C Hepatitis B Virus Pre-S2 Mutant Induces Aerobic Glycolysis through Mammalian Target of Rapamycin Signal Cascade PLoS One 2015 10 e0122373 25909713
110 Amann T Maegdefrau U Hartmann A GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis Am J Pathol 2009 174 1544 52 19286567
111 Guo H Zhou T Jiang D Regulation of Hepatitis B Virus Replication by the Phosphatidylinositol 3-Kinase-Akt Signal Transduction Pathway J Virol 2007 81 10072 80 17609269
112 Huang W Zhao F Huang Y Rapamycin Enhances HBV Production by Inducing Cellular Autophagy Hepat Mon 2014 14 e20719 25419217
113 Lin Y Deng W Pang J The microRNA-99 family modulates hepatitis B virus replication by promoting IGF-1R/PI3K/Akt/mTOR/ULK1 signaling-induced autophagy Cell Microbiol 2017 19
114 Xiang K Wang B Role of the PI3K-AKT-mTOR pathway in hepatitis B virus infection and replication Mol Med Rep 2018 17 4713 9 29328380
115 Sir D Tian Y Chen W Ann DK Yen T-SB Ou J-HJ The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication Proc Natl Acad Sci U S A 2010 107 4383 8 20142477
116 Wang X Lin Y Kemper T AMPK and Akt/mTOR signalling pathways participate in glucose-mediated regulation of hepatitis B virus replication and cellular autophagy Cell Microbiol 2020 22 e13131 31746509
117 Zachari M Ganley IG The mammalian ULK1 complex and autophagy initiation Essays Biochem 2017 61 585 96 29233870
118 Ro S-H Jung CH Hahn WS Distinct functions of Ulk1 and Ulk2 in the regulation of lipid metabolism in adipocytes Autophagy 2013 9 2103 14 24135897
119 Lin Y Wu C Wang X Hepatitis B virus is degraded by autophagosome-lysosome fusion mediated by Rab7 and related components Protein Cell 2019 10 60 6 29876903
120 Tian Y Sir D Kuo C-F Ann DK Ou J-HJ Autophagy required for hepatitis B virus replication in transgenic mice J Virol 2011 85 13453 6 21957292
121 Lin Y Wu C Wang X Synaptosomal-associated protein 29 is required for the autophagic degradation of hepatitis B virus FASEB J 2019 33 6023 34 30742775
122 Lin Y Wu C Wang X Glucosamine promotes hepatitis B virus replication through its dual effects in suppressing autophagic degradation and inhibiting MTORC1 signaling Autophagy 2020 16 548 61 31204557
123 Wang J Chen J Liu Y Hepatitis B Virus Induces Autophagy to Promote its Replication by the Axis of miR-192-3p-XIAP Through NF kappa B Signaling Hepatology 2019 69 974 92 30180281
124 Shaw RJ Cantley LC Ras, PI(3)K and mTOR signalling controls tumour cell growth Nature 2006 441 424 30 16724053
125 Menon S Yecies JL Zhang HH Chronic Activation of mTOR Complex 1 is Sufficient to Cause Hepatocellular Carcinoma Sci Signal 2012 5 ra24 22457330
126 Boyault S Rickman DS de Reyniès A Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets Hepatology 2007 45 42 52 17187432
127 Yang J Pi C Wang G Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells Biomed Pharmacother 2018 103 699 707 29680738
128 Guri Y Colombi M Dazert E mTORC2 Promotes Tumorigenesis via Lipid Synthesis Cancer Cell 2017 32 807 823.e12 29232555
129 Lee G Zheng Y Cho S Post-transcriptional Regulation of De Novo Lipogenesis by mTORC1-S6K1-SRPK2 Signaling Cell 2017 171 1545 1558.e18 29153836
130 Park EJ Lee JH Yu G-Y Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression Cell 2010 140 197 208 20141834
131 Lin C-W Zhang H Li M Pharmacological Promotion of Autophagy Alleviates Steatosis and Injury in Alcoholic and Non-alcoholic Fatty Liver Conditions in Mice J Hepatol 2013 58 993 9 23339953
132 Zhang H Yan S Khambu B Dynamic MTORC1-TFEB feedback signaling regulates hepatic autophagy, steatosis and liver injury in long-term nutrient oversupply Autophagy 2018 14 1779 95 30044707
133 Singh R Kaushik S Wang Y Autophagy regulates lipid metabolism Nature 2009 458 1131 5 19339967
134 Villanueva A Chiang DY Newell P Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma Gastroenterology 2008 135 1972 198411 18929564
135 Matter MS Decaens T Andersen JB Thorgeirsson SS Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends J Hepatol 2014 60 855 65 24308993
136 Wang C Wang X Su Z Fei H Liu X Pan Q The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth Oncol Rep 2015 34 1708 16 26239364
137 Chen Y Zhou X Research progress of mTOR inhibitors Eur J Med Chem 2020 208 112820 32966896
138 Toniato de Rezende Freschi J Cristelli MP Viana LA A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial Transplantation 2024 108 261 75 37525373
139 Tomita Y Uehara S Takiguchi S Nakamura M Effect of Mammalian Target of Rapamycin Inhibition on Activated Regulatory T-Cell Expansion in Kidney Transplantation Transplant Proc 2023 55 792 6 37100735
140 Nunes Ficher K Dreige Y Gessolo Lins PR Long-term Efficacy and Safety of Everolimus Versus Mycophenolate in Kidney Transplant Recipients Receiving Tacrolimus Transplantation 2022 106 381 90 33988338
141 Kwitkowski VE Prowell TM Ibrahim A FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma Oncologist 2010 15 428 35 20332142
142 Motzer RJ Escudier B Oudard S Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 2008 372 449 56 18653228
143 Yao JC Fazio N Singh S Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study Lancet 2016 387 968 77 26703889
144 Huynh H Chow KHP Soo KC RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma J Cell Mol Med 2009 13 1371 80 18466352
145 Hui IC-F Tung EK-K Sze KM-F Ching Y-P Ng IO-L Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma Liver Int 2010 30 65 75 19845851
146 Buitrago-Molina LE Pothiraju D Lamlé J Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage Hepatology 2009 50 500 9 19642171
147 Kudo M Finn RS Qin S Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Lancet 2018 391 1163 73 29433850
148 Koeberle D Dufour J-F Demeter G Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29) Ann Oncol 2016 27 856 61 26884590
149 Zhu AX Kudo M Assenat E Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial JAMA 2014 312 57 67 25058218
150 Schöniger-Hekele M Müller C Pilot study: rapamycin in advanced hepatocellular carcinoma Aliment Pharmacol Ther 2010 32 763 8 20629977
151 Yeo W Chan SL Mo FKF Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response BMC Cancer 2015 15 395 25962426
152 Sachdev JC Javed AY Weir AB A phase II study of temsirolimus in previously treated advanced hepatocellular carcinoma (HCC) JCO 2014 32 4098 4098
153 Baba HA Wohlschlaeger J Cicinnati VR Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma Liver Int 2009 29 399 405 18492014
154 Fornari F Milazzo M Chieco P MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells Cancer Res 2010 70 5184 93 20501828
155 Knox JJ Qin R Strosberg JR A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma Invest New Drugs 2015 33 241 6 25318437
156 Choo SP Chowbay B Ng QS A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma Eur J Cancer 2013 49 999 1008 23265712
157 Geissler EK Schnitzbauer AA Zülke C Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial Transplantation 2016 100 116 25 26555945
158 Schnitzbauer AA Filmann N Adam R mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors Ann Surg 2020 272 855 62 32889867
159 Lee K-W Kim SH Yoon KC Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial J Clin Med 2020 9 3264 33053849
160 Carracedo A Ma L Teruya-Feldstein J Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J Clin Invest 2008 118 3065 74 18725988
161 Tamburini J Chapuis N Bardet V Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways Blood 2008 111 379 82 17878402
162 Gupta M Ansell SM Novak AJ Kumar S Kaufmann SH Witzig TE Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2 Blood 2009 114 2926 35 19641186
163 Choo AY Yoon S-O Kim SG Roux PP Blenis J Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation Proc Natl Acad Sci U S A 2008 105 17414 9 18955708
164 Wagle N Grabiner BC Van Allen EM Response and acquired resistance to everolimus in anaplastic thyroid cancer N Engl J Med 2014 371 1426 33 25295501
165 Rodrik-Outmezguine VS Okaniwa M Yao Z Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor Nature 2016 534 272 6 27279227
166 Mahalingam D Medina EC Esquivel JA Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels Clin Cancer Res 2010 16 141 53 20028765
167 Marinov M Ziogas A Pardo OE AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001 Clin Cancer Res 2009 15 1277 87 19228731
168 Wendel H-G Malina A Zhao Z Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo Cancer Res 2006 66 7639 46 16885364
169 Majumder PK Febbo PG Bikoff R mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways Nat Med 2004 10 594 601 15156201
170 Murata K Tsukuda S Suizu F Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection Hepatology 2020 71 1533 45 31529730
171 Brooks DG Trifilo MJ Edelmann KH Teyton L McGavern DB Oldstone MBA Interleukin-10 determines viral clearance or persistence in vivo Nat Med 2006 12 1301 9 17041596
172 Peppa D Micco L Javaid A Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection PLoS Pathog 2010 6 e1001227 21187913
173 Wang Z Kawaguchi K Honda M Distinct notch signaling expression patterns between nucleoside and nucleotide analogues treatment for hepatitis B virus infection Biochem Biophys Res Commun 2018 501 682 7 29752943
174 Schnitzbauer AA Zuelke C Graeb C A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma BMC Cancer 2010 10 190 20459775
175 Su R-Y Ling S-B Shan Q-N Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study Hepatobiliary Pancreat Dis Int 2022 21 106 12 34583911
176 Rizell M Andersson M Cahlin C Hafström L Olausson M Lindnér P Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer Int J Clin Oncol 2008 13 66 70 18307022
177 Decaens T Luciani A Itti E Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma Dig Liver Dis 2012 44 610 6 22459565
178 Zhu AX Abrams TA Miksad R Phase 1/2 study of everolimus in advanced hepatocellular carcinoma Cancer 2011 117 5094 102 21538343
179 Shiah H-S Chen C-Y Dai C-Y Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma Aliment Pharmacol Ther 2013 37 62 73 23134470
180 Kelley RK Nimeiri HS Munster PN Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates Ann Oncol 2013 24 1900 7 23519998
181 Finn RS Poon RTP Yau T Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma J Hepatol 2013 59 1271 7 23928403
182 Zhang Y-Y Hu K-Q Rethinking the pathogenesis of hepatitis B virus (HBV) infection J Med Virol 2015 87 1989 99 25989114
183 Li J Cheng D Zhu M OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer Theranostics 2019 9 179 95 30662561
184 Xiong D Jin C Ye X TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway Cancer Sci 2018 109 3080 92 30098109
185 Zheng Y-L Li L Jia Y-X LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway Theranostics 2019 9 796 810 30809309
186 Wander SA Hennessy BT Slingerland JM Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy The Journal of Clinical Investigation 2011 121 1231 21490404
187 Wang C Cigliano A Jiang L 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice Hepatology 2015 61 200 13 25145583
188 Duvoux C Toso C mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation? Transplant Rev (Orlando) 2015 29 168 74 26071984
